prepared an intelligent legumain protease‐responsive macrophage‐based delivery system (LD‐MDS) via anchoring a legumain‐specific propeptide of melittin (legM) and cytotoxic soravtansine (DM4) prodrug onto the membrane of macrophages.[238] The resultant LD‐MDS could response to legumain protease and subsequently transform into DM4‐loaded exosome‐like nanovesicles (DENs), which can be internalized by metastatic 4T1 tumor cells. The gene discussed is LGMN; the disease is neoplasm.